GlassScriptPhysician profile
Mary Nguyen
NPI 1427599729
$4,908.07
in general payments reported to CMS, 2019-2025
27 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $849 · 2023: $1,182 · 2024: $1,154 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,862.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,496.60 | 2021-2025 | |
| Ucb, INC. | $896.95 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Neurocrine Biosciences, INC. | $510.72 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $281.20 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $229.01 | 2022-2023 | |
| Argenx US, INC. | $219.83 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $192.95 | 2022-2023 | |
| Pfizer INC. | $152.46 | 2025 | |
| Lilly USA, LLC | $116.22 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Astrazeneca Pharmaceuticals LP | $91.69 | 2021 | |
| Acadia Pharmaceuticals INC | $84.92 | 2022-2023 | Nuplazid |
| Amgen INC. | $84.58 | 2022 | |
| Lundbeck LLC | $82.20 | 2024-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $78.16 | 2021-2022 | |
| Grifols USA, LLC | $66.93 | 2023 | Gamunex-C |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $54.39 | 2023 | Zeposia |
| Ge Healthcare | $42.98 | 2025 | |
| Csl Behring | $34.46 | 2024 | Hizentra |
| Eisai INC. | $34.19 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $25.93 | 2024 | Dysport |
| Biogen, INC. | $24.76 | 2025 | Tysabri, Vumerity |
| Collegium Pharmaceutical, INC. | $23.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.66 | 2025 | Rexulti |
| Mdd US Operations, LLC | $17.41 | 2025 | Qelbree |
| Impel Pharmaceuticals INC. | $13.54 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.